These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Imaging in Multiple Sclerosis: Diagnosis and Management. Mukherji SK Neuroimaging Clin N Am; 2017 May; 27(2):xv. PubMed ID: 28391793 [No Abstract] [Full Text] [Related]
4. Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - NO. Jonkman L Mult Scler; 2017 Mar; 23(3):374-375. PubMed ID: 28260417 [No Abstract] [Full Text] [Related]
5. Quantification of blood brain barrier using DCE MRI in multiple sclerosis - Technical issues and its possible role in routine clinical practice. Gupta RK Neurol India; 2018; 66(3):671-672. PubMed ID: 29766921 [No Abstract] [Full Text] [Related]
6. Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - YES. Bagnato F; Gore JC Mult Scler; 2017 Mar; 23(3):372-373. PubMed ID: 28260420 [No Abstract] [Full Text] [Related]
7. MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. Leocani L; Rocca MA; Comi G Curr Opin Neurol; 2016 Jun; 29(3):243-53. PubMed ID: 27058224 [TBL] [Abstract][Full Text] [Related]
8. Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. Sastre-Garriga J; Pareto D; Rovira À Neuroimaging Clin N Am; 2017 May; 27(2):289-300. PubMed ID: 28391787 [TBL] [Abstract][Full Text] [Related]
9. Correlation of clinical findings and brain volume data in multiple sclerosis. Fragoso YD; Wille PR; Abreu M; Brooks JBB; Dias RM; Duarte JA; Farage L; Finkelsztejn A; Frohlich AC; Goncalves MVM; Guedes BVS; Medeiros L; Oliveira RA; Ribas FD; da Rocha FCG; Santos GAC; Scorcine C; da Silveira GL; Spedo CT; Tauil CB; Varela JS; Vieira VLF; J Clin Neurosci; 2017 Oct; 44():155-157. PubMed ID: 28676309 [TBL] [Abstract][Full Text] [Related]
11. [The role of MRI in measuring the effectivity of disease modifying treatments I]. Tóth E; Bencsik K; Vörös E; Fricska-Nagy Z; Füvesi J; Rajda C; Csomor A; Palkó A; Vécsei L; Kincses ZT Ideggyogy Sz; 2018 Mar; 71(3-04):77-80. PubMed ID: 29889465 [TBL] [Abstract][Full Text] [Related]
12. The use of MRI as an outcome measure in clinical trials. Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836 [TBL] [Abstract][Full Text] [Related]
13. Visualization of cortical MS lesions with MRI need not be further improved - NO. Mainero C; Granberg T Mult Scler; 2017 Jan; 23(1):17-19. PubMed ID: 27566449 [No Abstract] [Full Text] [Related]
14. Visualization of cortical MS lesions with MRI need not be further improved - YES. Geurts JJ; Chard DT Mult Scler; 2017 Jan; 23(1):15-17. PubMed ID: 27566450 [No Abstract] [Full Text] [Related]
15. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Uher T; Vaneckova M; Sobisek L; Tyblova M; Seidl Z; Krasensky J; Ramasamy D; Zivadinov R; Havrdova E; Kalincik T; Horakova D Mult Scler; 2017 Jan; 23(1):51-61. PubMed ID: 27053635 [TBL] [Abstract][Full Text] [Related]
19. MRI and multiple sclerosis--the evolving role of MRI in the diagnosis and management of MS: the radiologist's perspective. Cahalane AM; Kearney H; Purcell YM; McGuigan C; Killeen RP Ir J Med Sci; 2018 Aug; 187(3):781-787. PubMed ID: 29177917 [TBL] [Abstract][Full Text] [Related]
20. Evidence for neuroprotection and remyelination using imaging techniques. Arnold DL Neurology; 2007 May; 68(22 Suppl 3):S83-90; discussion S91-6. PubMed ID: 17548574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]